2023
DOI: 10.1016/j.gastrohep.2023.01.008
|View full text |Cite
|
Sign up to set email alerts
|

Predictive models for hepatocellular carcinoma development after sustained virological response in advanced hepatitis C

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 27 publications
0
2
0
Order By: Relevance
“…Furthermore, emerging evidence suggests a persistent risk of HCC in CHC patients post-DAAs therapy, even after achieving SVR[ 10 ]. Therefore, in the effort to eradicate HCV and subsequently minimize its associated complications, there are countless studies focused on identifying high-risk patient profiles prone to post-SVR complications[ 11 , 12 ].…”
Section: Introductionmentioning
confidence: 99%
“…Furthermore, emerging evidence suggests a persistent risk of HCC in CHC patients post-DAAs therapy, even after achieving SVR[ 10 ]. Therefore, in the effort to eradicate HCV and subsequently minimize its associated complications, there are countless studies focused on identifying high-risk patient profiles prone to post-SVR complications[ 11 , 12 ].…”
Section: Introductionmentioning
confidence: 99%
“…The study’s design precluded the determination of the optimal timing for patient assessment during follow-up, given the disparate timelines among participants. Notably, various authors propose risk-stratifying patients at a specific juncture, namely, 12 weeks posttreatment upon achieving SVR 7,8 . The absence of a protocolized serial evaluation of peripheral blood mononuclear cells between the time of SVR and the occurrence of HCC tampers the confidence of using TIM-3 hi and CD38 + at SVR12 to risk-stratify patients.…”
mentioning
confidence: 99%